The Carlyle Group Inc. (CG)
Automate Your Wheel Strategy on CG
With Tiblio's Option Bot, you can configure your own wheel strategy including CG - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CG
- Rev/Share 13.4329
- Book/Share 18.6393
- PB 3.3574
- Debt/Equity 1.5936
- CurrentRatio 0.0
- ROIC -0.2084
- MktCap 22635498900.0
- FreeCF/Share -3.5042
- PFCF -17.9234
- PE 17.9526
- Debt/Assets 0.427
- DivYield 0.0224
- ROE 0.2143
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
Upgrade | CG | Citigroup | Neutral | Buy | -- | $65 | July 10, 2025 |
Upgrade | CG | TD Cowen | Hold | Buy | -- | $56 | May 14, 2025 |
Downgrade | CG | Oppenheimer | Outperform | Perform | -- | -- | March 19, 2025 |
Upgrade | CG | Wolfe Research | Peer Perform | Outperform | -- | $60 | Jan. 3, 2025 |
Initiation | CG | Wells Fargo | -- | Equal Weight | -- | $42 | Sept. 12, 2024 |
Initiation | CG | Redburn Atlantic | -- | Buy | -- | $55 | Aug. 27, 2024 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
Published: March 17, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ: BLUE).
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
Published: March 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
Read More
bluebird bio Investor Alert: Is the Proposed Acquisition of bluebird bio Fair to bluebird bio Investors - Kehoe Law Firm, P.C. Investigating - BLUE
Published: March 12, 2025 by: Accesswire
Sentiment: Neutral
PHILADELPHIA, PA / ACCESS Newswire / March 12, 2025 / Kehoe Law Firm, P.C. continues its investigation on behalf of investors of bluebird bio (NASDAQ:BLUE) regarding the adequacy and fairness of the proposed acquisition of bluebird bio by "funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP ("SK Capital") in collaboration with a team of highly experienced biotech executives.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
Published: March 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
Published: March 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ: BLUE).
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
Read More
PAX vs. CG: Which Stock Is the Better Value Option?
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Financial - Investment Management stocks have likely encountered both Patria Investments (PAX) and Carlyle Group (CG). But which of these two stocks is more attractive to value investors?
Read More
NSM Insurance Group Announces Definitive Agreement for New Mountain Capital to Acquire Its U.S. Commercial Insurance Division
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
CONSHOHOCKEN, Pa. , Feb. 24, 2025 /PRNewswire/ -- NSM Insurance Group ("NSM"), a global specialty insurance provider, announced today it has signed a definitive agreement to sell its U.S. commercial insurance division to New Mountain Capital ("New Mountain"), a leading growth-oriented investment firm with over $55 billion in assets under management.
Read More
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc.
Published: February 21, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 21, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by bluebird bio, Inc. (NASDAQ: BLUE) and its board of directors concerning the proposed acquisition of the company by Carlyle (NASDAQ: CG) and SK Capital Partners, LP. Stockholders will receive $3.00 and a contingent value right of $6.84 for each share of bluebird bio stock that they hold.
Read More
bluebird bio Stock Alert - Kehoe Law Firm, P.C. Investigating the Fairness and Adequacy of the Proposed Acquisition of bluebird bio by Investment Firms in Collaboration with Biotech Execs
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
PHILADELPHIA, PA / ACCESS Newswire / February 21, 2025 / Kehoe Law Firm, P.C. is investigating potential claims on behalf of investors of bluebird bio (NASDAQ:BLUE) regarding the adequacy and fairness of the proposed acquisition of bluebird bio by "funds managed by global investment firms Carlyle (NASDAQ:CG) and SK Capital Partners, LP ("SK Capital") in collaboration with a team of highly experienced biotech executives.
Read More
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
Published: February 21, 2025 by: Business Wire
Sentiment: Neutral
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP (“SK Capital”) in collaboration with a team of highly experienced biotech executives. David Meek, former CEO of Mirati Therapeutics and Ipsen, is expected to become CEO of bluebird upon closing. Carlyle and SK Capital will provide bluebird prim.
Read More
Higher Fee Revenues, Brighter Outlook Boost Mood Of Private Equity's Big 4
Published: February 21, 2025 by: Seeking Alpha
Sentiment: Positive
Record revenues from management fees and a brighter outlook for M&A in the year ahead helped private equity's Big Four close 2024 on a high note. The average net positivity score for the four largest listed alternative asset managers - Apollo Global Management, Blackstone, The Carlyle, and KKR - rose to its highest level in several years, according to an S&P Global Market Intelligence analysis.
Read More
Farmfront Announces Commercial Partnership with BF Group to Supply Irrigation Solutions
Published: February 18, 2025 by: Business Wire
Sentiment: Neutral
MILAN--(BUSINESS WIRE)--Farmfront Group (“Farmfront”), a leading global platform of irrigation providers backed by global investment firm Carlyle (NASDAQ: CG), announces that it has signed a strategic commercial partnership and supply agreement with BF International Best Fields Best Foods Limited (“BFI”), a company of BF S.p.A. group (“BF Group”) to provide irrigation solutions to its subsidiary, BFI. The agreement is intended to support BF Group's international expansion plans and support agro.
Read More
The old economy is still very much out of favor right now, says Carlyle's Jeff Currie
Published: February 13, 2025 by: CNBC Television
Sentiment: Negative
Jeff Currie, Carlyle chief strategy officer of energy pathways, joins 'Squawk Box' to discuss impact of President Trump's tariffs on commodities, impact of steel and aluminum tariffs on producer inflation, state of U.S. oil production, and more.
Read More
Carlyle Group enters Indian auto parts industry with Highway-Roop platform buy
Published: February 13, 2025 by: Reuters
Sentiment: Positive
U.S.-based investment firm Carlyle Group has entered India's auto components market by buying a controlling stake in an entity formed by the combination of Indian auto parts companies Highway Industries and Roop Automotives.
Read More
Carlyle Q4 Earnings Miss Estimates, Revenues & AUM Increase Y/Y
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Negative
CG's fourth-quarter 2024 results benefit from growth in segment fee revenues. Yet, an increase in expenses acts as a headwind.
Read More
The Carlyle Group Inc. (CG) Q4 2024 Earnings Call Transcript
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Neutral
The Carlyle Group Inc. (NASDAQ:CG ) Q4 2024 Earnings Conference Call February 11, 2025 8:30 AM ET Company Participants Daniel Harris - Head of Investor Relations Harvey Schwartz - Chief Executive Officer John Redett - Chief Financial Officer and Head of Corporate Strategy Conference Call Participants Alexander Blostein - Goldman Sachs Brendan O'Brien - Wolfe Research Patrick Davitt - Autonomous Research Brian Bedell - Deutsche Bank Brian McKenna - Citizens JMP Glenn Schorr - Evercore ISI Benjamin Budish - Barclays Daniel Fannon - Jefferies William Katz - TD Cowen Kenneth Worthington - JPMorgan Michael Cyprus - Morgan Stanley Kyle Voigt …
Read More
Carlyle's slower fee growth draws questions as private-equity firm's stock falls
Published: February 11, 2025 by: Market Watch
Sentiment: Negative
Carlyle Group Inc.'s stock fell 5% on Tuesday after the private-equity firm signaled a slowdown in its fee-related earnings growth in 2025, as it leans on its private-credit arm to increase its profit.
Read More
About The Carlyle Group Inc. (CG)
- IPO Date 2012-05-03
- Website https://www.carlyle.com
- Industry Asset Management
- CEO Harvey Mitchell Schwartz
- Employees 2300